3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
16
HER2-positive Breast Cancer
2
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Patient Preference
1
Inflammatory Breast Neoplasms
1
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
1
HER2-Positive Primary Breast Cancer
1
HER2+ Breast Cancer
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Anatomic Stage IA Breast Cancer AJCC v8
1
Interventions
Cyclophosphamide
10
Radiotherapy
6
Epirubicin
6
Paclitaxel
5
Docetaxel
5
Trastuzumab
4
Fluorouracil
4
Doxorubicin
4
Tamoxifen
3
Neoadjuvant Therapy
3
pertuzumab
2
Surgical Procedures, Operative
2
Filgrastim
2
ferric carboxymaltose
1
Thiotepa
1
Taxes
1
Razoxane
1
Radiation
1
Prochlorperazine
1
Peripheral Blood Stem Cell Transplantation
1
Palonosetron
1
Microarray Analysis
1
Methotrexate
1
Injections, Subcutaneous
1
Immunohistochemistry
1
Granulocyte Colony-Stimulating Factor
1
Granisetron
1
Dexrazoxane
1
Dexamethasone
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Inflammatory Breast Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts